Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells.
about
Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune RegulationCyclooxygenase-2 promotes tumor growth and suppresses tumor immunityThe Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor BedsMyeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor MicroenvironmentMultiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancerHampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancerA review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methodsCOX-2 and PGE2-dependent immunomodulation in breast cancerTargeting inflammation: multiple innovative ways to reduce prostaglandin E₂Inhibition of cyclooxygenase-2 in hematopoietic cells results in salt-sensitive hypertensionProstaglandin E receptor 4 (EP4) promotes colonic tumorigenesis.The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer ProgressionPeripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapyCoordinated regulation of myeloid cells by tumoursEvaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (MDSC) adoptive transfer in mouse models of autoimmunity and allograft rejection.Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte functionA paradoxical role for myeloid-derived suppressor cells in sepsis and traumaMyeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice.Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response.TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesisAll Trans Retinoic Acid, Transforming Growth Factor β and Prostaglandin E2 in Mouse Plasma Synergize with Basophil-Secreted Interleukin-4 to M2 Polarize Murine MacrophagesTumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agentStem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action.A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis.Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravisGastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2.Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancerTLR Signalling Pathways Diverge in Their Ability to Induce PGE2.Effects of notch signaling on regulation of myeloid cell differentiation in cancer.Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors.Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.Myeloid-derived suppressor cells contribute to Staphylococcus aureus orthopedic biofilm infection.Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function.Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.Possible link between cyclooxygenase-inhibiting and antitumor properties of propofol.Prostaglandin catabolic enzymes as tumor suppressors.Myeloid-derived suppressor cells in transplantation and cancer
P2860
Q26741252-AB6EA640-D240-4890-8E30-BEF47B4B3142Q26778534-542872E3-8806-48B5-8885-BB6B980386ECQ26799120-FA6A0BA0-0D5B-4D45-A956-4B7D0DC9CDDCQ26799126-C297717F-7219-49C7-8723-7147E24A0211Q26828414-E9E4A719-9B73-4AD5-9448-C9B7021B9233Q26863418-D6BFCCE6-AA53-4D87-A643-1DA1186DA00DQ26998969-3A521959-1AB0-44F3-980F-C2E9AC0EE469Q27003937-DBC5D731-264F-4791-A765-D22B928237F1Q27008521-EBC47BC1-06CD-4B1A-ACA6-528B5B9763E1Q27331781-8617DB42-4748-4BF2-B268-09ACC8D0FD30Q27340480-772A6C8A-B048-4667-B828-0BAA80C9F3E2Q28076760-A9699045-E768-4CDD-9009-C118673A49F7Q28394867-B3A82FB0-7D12-4175-A6F1-42416B140163Q28395157-26556766-28AD-4C26-9BEB-66276675DF80Q33754157-CFBAAE30-3FFB-465B-9A87-7906B0D43E83Q34009960-D992214F-EE6D-41AF-B805-E643C32534D7Q34699543-A6035835-B024-4A9D-A0D8-B191203632C6Q34903354-D7365EC8-6FE4-43D1-8D38-0A8CF7950A74Q35553327-AD9E5E60-9384-4274-B071-AA5F3DF7D2C6Q35887319-FD6FDF3D-7800-4B83-A6F7-44EA6EE84BEAQ36018144-6FF00EAF-A5DC-4C66-94DC-3D20CEF15713Q36108579-0EF1FAD7-9887-46BA-B84F-5BB7516E9984Q36224968-753231B9-19C3-4830-BAAA-5D71B139D6B1Q36383090-F5E0A371-124E-4ADC-B068-6CA6AB1BE236Q36483712-EC011A72-4C5F-4084-A1D3-32CF458916CFQ36494604-FB2367C7-4A3B-4739-A773-F3562C3C6188Q36643655-62C37D4C-5612-4040-B634-D1420F14DBF8Q36669016-2A9E795F-E3C4-4A1A-B042-4352773CA742Q36711029-3FFF7456-30E8-45DB-B925-BA2835B81D3EQ36896764-0E19D15C-1CCA-4304-9DCE-F1EBDE29CE77Q37223021-C2AFC54A-55B1-4E90-904E-088732CCA408Q37456808-BEB1B432-7FB4-4A55-A391-DF26B52BF980Q37683666-D711EB3E-1631-43E3-A29B-66D7DC8170F9Q37701635-F27AF8AD-7478-4C54-B507-58F2D0B1D954Q37732211-8EC169C2-B5E4-4389-ADC7-E5E534B5E73EQ37808561-9D34A91D-AFB2-4EFA-A05D-6BF61969DD01Q37829504-12BC5748-B2CF-41B2-8A2A-15752D3FBEEBQ37879601-4E373FD5-9321-4DF3-8E85-F227B109CFE9Q37948688-ECF9AEC7-9C14-448B-8308-37D38B74BF1BQ38005601-16CEEE9A-3837-4EBF-9461-CE9FE5BF4FD3
P2860
Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Pivotal Advance: Tumor-mediate ...... ₂ catabolism in myeloid cells.
@en
Pivotal Advance: Tumor-mediate ...... ₂ catabolism in myeloid cells.
@nl
type
label
Pivotal Advance: Tumor-mediate ...... ₂ catabolism in myeloid cells.
@en
Pivotal Advance: Tumor-mediate ...... ₂ catabolism in myeloid cells.
@nl
prefLabel
Pivotal Advance: Tumor-mediate ...... ₂ catabolism in myeloid cells.
@en
Pivotal Advance: Tumor-mediate ...... ₂ catabolism in myeloid cells.
@nl
P2093
P356
P1476
Pivotal Advance: Tumor-mediate ...... E₂ catabolism in myeloid cells
@en
P2093
Evgeniy Eruslanov
Irina Daurkin
Johannes Vieweg
P304
P356
10.1189/JLB.1209821
P577
2010-06-29T00:00:00Z